GUGGENHIME ANDREW sold $573K of PCVX
GUGGENHIME ANDREW (PRESIDENT AND CFO) sold 10,000 shares of Vaxcyte, Inc. (PCVX) at an average of $57.28 ($57.16–$57.76, $0.57M total) across 2 trades on 2026-07-06 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the same-day open-market sale by the company’s President & CFO, totaling ~$572.8K across two trades.
Market read
Traders may note the insider sale for sentiment/positioning, but there is no new operational or financial catalyst in the text.
What to watch
The sale is explicitly pre-arranged under Rule 10b5-1, which often reduces the signal-to-noise versus discretionary selling.
Background
The article is a SEC Form 4 insider transaction disclosure for Vaxcyte, Inc. (PCVX).
Ticker impact
Vaxcyte’s President & CFO Andrew Guggenheim sold about 10,000 shares in open-market transactions on 2026-07-06 at ~$57.16–$57.76.
Likely limited near-term impact; any effect is more sentiment/flow-related than fundamentals.
The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arrangement and no accompanying company-specific news (earnings, guidance, trials, deals).
Market effects
No clear sector read-through; this is company-specific insider liquidity activity.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still be interpreted as reduced confidence by some traders.
Key entities
- issuerVaxcyte, Inc.
Subject of the Form 4 insider sale by its President & CFO.
- insiderAndrew Guggenheim
President and CFO who sold shares under a pre-arranged 10b5-1 plan.
